Cuál es el precio por Moleculin Biotech, Inc. (MBRX)

Precio por Moleculin Biotech, Inc. (MBRX) es de$0.6155

Cuál es la capitalización de mercado por Moleculin Biotech, Inc. (MBRX)

Capitalización de mercado por Moleculin Biotech, Inc. (MBRX) es $3.28M

Moleculin Biotech, Inc. (MBRX) EPS

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Año	EPS	Cambiar
Not enough data for the provided dates.

Año

EPS

Cambiar

Not enough data for the provided dates.

Empresa	EPS	Diferencia de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Empresa

EPS

Diferencia de EPS

País